Read this company snapshot
Daily valuation snapshot
Lyell Immunopharma, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $8.71
- Market capitalization (USD)
- $213,439,778.11
- Price / earnings (TTM)
- Not reported
- Price / book
- 0.91
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research LYEL in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research LYEL in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The company develops therapies using various approaches, such as c-Jun overexpression and NR4A3 gene knockout, to endow functional resistance to exhaustion; Epi-R to generate population of stem-like T cells with reduced exhaustion and improved proliferation and antitumor activity; CD62L positive enrichment to generate CAR T cells with enhanced antitumor activity; and Stim-R, a proprietary synthetic-cell mimetic. It is also developing IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate that is in Phase 1/2 clinical development for the treatment of patients with aggressive relapsed/refractory large B-cell non-Hodgkin lymphoma; and solid tumors program which is in preclinical trial targeting solid tumor indications. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing LYEL with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $8.71 |
| Market capitalization (USD) | $213,439,778.11 |
| Price / earnings (TTM) | Not reported |
| Price / book | 0.91 |
No matching rows. Clear the filter to see all records.
Read LYEL's valuation metrics
Company size
Lyell Immunopharma, Inc. Common Stock's recorded market capitalization is $213,439,778.11. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
LYEL's recorded price-to-book ratio is 0.91. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Lyell Immunopharma, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about LYEL. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow LYEL's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.